Market Overview

UPDATE: JP Morgan Upgrades The Medicines Company to Overweight on Pipeline Outlook

Related MDCO
Bank Of America Q3 Small & Mid-Cap Biotech Preview
BACTIVTM Phase 3 SOLO II Trial Results Published In The Journal Clinical Infectious Diseases

JP Morgan raised its rating on The Medicines Company (NASDAQ: MDCO) from Neutral to Overweight and increased its price target from $28 to $32.

JP Morgan noted, "This morning the company reported earlier-than-expected positive top-line Phase 3 results from oritavancin's SOLO-1 trial (in acute skin infections), but the crux of our call is on MDCO's overall risk/reward at current levels. Indeed, we believe the company's Angiomax franchise plus the balance sheet is worth nearly $20/sh alone, thus providing a solid value foundation. Then there's upside optionality from the remaining commercial portfolio and pipeline, including Recothrom, Cleviprex, cangrelor, oritavancin and IONSYS. We believe the scarcity of the company's acute-care-hospital–based infrastructure is also a key component to the story."

The Medicines Company closed at $22.29 on Wednesday.

Latest Ratings for MDCO

DateFirmActionFromTo
Oct 2014Credit SuisseMaintainsNeutral
Apr 2014Leerink SwannDowngradesOutperformMarket Perform
Apr 2014Piper JaffrayDowngradesOverweightNeutral

View More Analyst Ratings for MDCO
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Upgrades Intraday Update Analyst Ratings

 

Related Articles (MDCO)

Around the Web, We're Loving...

Get Benzinga's Newsletters